US75943R1023 - Common Stock
RELAY THERAPEUTICS INC
NASDAQ:RLAY (9/18/2024, 8:25:58 PM)
After market: 7.56 -0.02 (-0.26%)7.58
-0.02 (-0.26%)
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 309 full-time employees. The company went IPO on 2020-07-16. The firm is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
RELAY THERAPEUTICS INC
399 Binney Street, 2nd Floor
Cambridge MASSACHUSETTS 02139
P: 16173708837
CEO: Sanjiv K. Patel
Employees: 309
Website: https://relaytx.com/
Investors weren't happy with the company's latest effort at capital-raising.
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock ...
Here you can normally see the latest stock twits on RLAY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: